Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Rhea-AI Summary

Agomab (Nasdaq: AGMB) announced the USPTO granted U.S. Patent No. 12,577,230 for AGMB-447, its investigational inhaled, lung-restricted small molecule ALK5 inhibitor. The patent covers composition of matter in the U.S. through at least 2041, excluding potential extensions.

AGMB-447 is in a Phase 1b study for idiopathic pulmonary fibrosis (IPF); healthy-subject data were described as positive and patient-cohort results are expected later in 2026. AGMB-447 is not approved and its safety and efficacy remain unestablished.

Positive

• U.S. composition patent secured through at least 2041
• Patent covers AGMB-447 chemistry, strengthening U.S. IP position
• Phase 1b progressing with positive healthy-subject data reported

Negative

• AGMB-447 remains investigational; safety and efficacy unestablished
• Patient-cohort Phase 1b results pending later in 2026
• Patent term excludes potential patent term extensions

News Market Reaction – AGMB

-7.70%

13 alerts

-7.70% Session close to close

+10.4% Peak Tracked

-14.2% Trough Tracked

$658.92M Market Cap

0.8x Rel. Volume

In the Mar 26 session, AGMB declined 7.70%, reflecting a notable negative market reaction. Argus tracked a peak move of +10.4% during that session. Argus tracked a trough of -14.2% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.7% in the session following this news. A negative reaction despite the issuance o...

Analysis

The stock moved -7.7% in the session following this news. A negative reaction despite the issuance of U.S. Patent No. 12,577,230 would contrast with the constructive nature of stronger IP protection for AGMB-447 through at least 2041. Historically, Agomab’s IPO at $16.00 triggered only a modest -0.38% move, offering little evidence of sharp downside on positive events. Any pronounced decline around this patent update would likely reflect broader concerns about clinical execution or market risk appetite rather than the patent itself.

Key Figures

U.S. patent number: 12,577,230 Trial phase: Phase 1b IP protection term: Through at least 2041

3 metrics

U.S. patent number 12,577,230 U.S. patent granted covering AGMB-447 composition of matter

Trial phase Phase 1b Current study of AGMB-447 in Idiopathic Pulmonary Fibrosis

IP protection term Through at least 2041 U.S. IP protection for AGMB-447, excluding any term extensions

Historical Context

1 past event · Latest: Feb 09 (Positive)

Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 09	IPO completion	Positive	-0.4%	Closing of IPO at $16.00 per ADS raising about $200M gross proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Limited post-IPO history: the IPO priced at $16.00 saw a slight next-day dip, while today’s patent news coincides with a stronger upside move.

Recent Company History

In the past months, Agomab completed its IPO, issuing 12,500,000 ADSs at $16.00 for roughly $200.0 million in gross proceeds, and began trading on the Nasdaq Global Select Market on February 6, 2026. That event saw a modest -0.38% reaction. Today’s U.S. patent grant for AGMB-447 extends protection through at least 2041, complementing the company’s transition from private to public markets and reinforcing IP around its fibrosis pipeline.

Key Terms

united states patent and trademark office (uspto), composition of matter, alk5, tgfβr1, +4 more

8 terms

united states patent and trademark office (uspto) regulatory

"the United States Patent and Trademark Office (USPTO) has granted U.S. Patent"

The United States Patent and Trademark Office (USPTO) is the federal agency that examines and grants patents and registers trademarks, giving creators official, time-limited rights to inventions and brand names. For investors, USPTO decisions matter because patents and trademarks can protect a company’s products and brand from copycats, support higher pricing or licensing revenue, and influence a company’s value and legal risk—think of it as an official lock and record that helps secure a business’s competitive edge.

composition of matter regulatory

"U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447"

Composition of matter describes the specific chemical makeup and structure of a substance — essentially the “recipe” of which atoms or molecules are present and how they are arranged. For investors, it matters because that precise recipe is what patents, regulatory approvals, and product claims protect; control over a unique composition can create market exclusivity, influence manufacturing costs, and drive a company’s valuation or licensing potential.

alk5 medical

"small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study"

A receptor protein on cell surfaces that receives signals from the TGF‑β pathway and helps control cell growth, scarring and inflammation. Think of it like a traffic signal that tells cells to slow down, change behavior or produce scar tissue; drugs that block or tweak ALK5 can alter those signals, so progress in ALK5-targeting drugs can materially affect the prospects and value of biotech firms developing treatments for fibrosis, cancer, or related conditions.

tgfβr1 medical

"small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study"

TGFβR1 is a protein on the surface of cells that acts like a lock for signals from the molecule TGF‑β; when the key fits, it triggers internal changes that control cell growth, scarring and immune responses. Investors care because drugs that block or modify this receptor can alter disease progression in areas like cancer, fibrosis and autoimmune disorders, affecting clinical outcomes, regulatory risk and commercial potential.

phase 1b medical

"currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

idiopathic pulmonary fibrosis (ipf) medical

"Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis (IPF)"

A chronic lung disease in which the tissue of the lungs gradually becomes scarred and stiff, making it harder to breathe and get enough oxygen. For investors, IPF matters because it drives demand for treatments, shapes the commercial opportunity and clinical trial risk for drug developers, and can influence a company’s regulatory milestones and long‑term revenue potential; think of it as a market shaped by urgent medical need and high development risk.

intellectual property (ip) regulatory

"This patent provides intellectual property (IP) protection for AGMB-447"

Intellectual property (IP) is the legal ownership of ideas a company creates—such as inventions, brand names, designs, software code or creative works—protected through patents, trademarks, copyrights or trade secrets. For investors it matters because IP can act like a company’s recipe or blueprint, creating a barrier to competitors, enabling exclusive revenue streams or licensing income, and therefore influencing future profits and valuation.

investigational drug regulatory

"AGMB-447 is an investigational drug and not approved by any regulatory authority"

An investigational drug is a medicine that is still being tested and has not yet received full regulatory approval for general use. Investors care because the drug’s success or failure in studies and regulatory reviews can dramatically change a company’s future revenue and value — similar to backing a prototype product that may or may not clear safety and effectiveness checks before reaching customers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company’s investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This patent provides intellectual property (IP) protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions.

“The issuance of this patent is a significant milestone that solidifies the foundational IP for AGMB-447 in the U.S.,” commented Tim Knotnerus, Chief Executive Officer at Agomab. “Building a global patent portfolio for AGMB-447 is an important step in our mission to address the high unmet medical need for people living with IPF. Following the positive healthy subject data for AGMB-447, we look forward to the results of the IPF patient cohort of the Phase 1b study later this year.”

AGMB-447 is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established. 

About AGMB-447
AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF). TGFβ is the master regulator of fibrosis, which is the key process driving IPF disease progression. AGMB-447 is specifically designed to inhibit ALK5 in the lung while avoiding clinically relevant systemic exposure through local administration via inhalation and rapid hydrolyzation in plasma. Through AGMB-447, Agomab aims to offer a potentially safe and effective novel anti-fibrotic therapeutic option to IPF patients.

About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Cautionary Note Regarding Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding Agomab’s focus on the discovery and development of its pipeline of novel product candidates for chronic fibrotic disorders and the validity and duration of IP protection for AGMB-447 in the U.S., as well as statements regarding future data readouts. Forward-looking statements are based on Agomab’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the risks inherent in biopharmaceutical product development and the risk that we may not be able to successfully maintain, enforce and/or defend our IP for AGMB-447. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” section of the registration statement filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Agomab undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information in this announcement as current or accurate after its publication date.

Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143
        
Media
Gretchen Schweitzer
Trophic Communications
E-Mail: agomab@trophic.eu
Phone: +49 172 861 8540

Attachment

• 20260326_AGMB-447 US patent_FINAL

FAQ

What U.S. patent did Agomab (AGMB) receive for AGMB-447 on March 26, 2026?

Agomab received U.S. Patent No. 12,577,230 for AGMB-447, covering composition of matter. According to Agomab, this patent secures U.S. intellectual property protection for AGMB-447 through at least 2041, excluding any potential patent term extensions.

What is AGMB-447 and what stage is the AGMB (AGMB) drug in as of March 26, 2026?

AGMB-447 is an investigational inhaled, lung-restricted ALK5 (TGFβR1) inhibitor in a Phase 1b study. According to Agomab, healthy-subject data were positive and the IPF patient cohort readout is expected later in 2026.

How long does the new U.S. patent protect AGMB-447 for Agomab (AGMB)?

The patent provides U.S. protection for AGMB-447 through at least 2041. According to Agomab, that timeframe excludes any potential patent term extensions that could lengthen protection.

Does the AGMB-447 patent approval mean the drug is approved for IPF for Agomab (AGMB)?

No — the patent is an intellectual property milestone, not a regulatory approval. According to Agomab, AGMB-447 is investigational and its safety and efficacy have not been established by any regulatory authority.

When will Agomab (AGMB) report Phase 1b IPF patient-cohort results for AGMB-447?

Agomab expects to report Phase 1b IPF patient-cohort results later in 2026. According to Agomab, healthy-subject results were positive and the company is awaiting patient-cohort data this year.